المؤلفون: IACCARINO, LUCA, GATTO, MARIELE, ZEN, MARGHERITA, DORIA, ANDREA, Bartoloni, Elena, Carli, Linda, Ceccarelli, Fulvia, Conti, Fabrizio, De Vita, Salvatore, Ferraccioli, Gianfranco, Galeazzi, Mauro, Gerli, Roberto, Govoni, Marcello, Gremese, Elisa, Iuliano, Annamaria, Mansutti, Elena, Moroni, Gabriella, Mosca, Marta, Nalli, Cecilia, Naretto, Carla, Padovan, Melissa, Palma, Lavinia, Raffiotta, Francesca, Roccatello, Dario, Tincani, Angela, Valesini, Guido

المساهمون: Iaccarino, Luca, Bartoloni, Elena, Carli, Linda, Ceccarelli, Fulvia, Conti, Fabrizio, De Vita, Salvatore, Ferraccioli, Gianfranco, Galeazzi, Mauro, Gatto, Mariele, Gerli, Roberto, Govoni, Marcello, Gremese, Elisa, Iuliano, Annamaria, Mansutti, Elena, Moroni, Gabriella, Mosca, Marta, Nalli, Cecilia, Naretto, Carla, Padovan, Melissa, Palma, Lavinia, Raffiotta, Francesca, Roccatello, Dario, Tincani, Angela, Valesini, Guido, Zen, Margherita, Doria, Andrea

مصطلحات موضوعية: Adult, Antibodies, Monoclonal, Murine-Derived, Antirheumatic Agent, Dose-Response Relationship, Drug, Drug Monitoring, Drug Resistance, Female, Human, Immunosuppression, Italy, Lupus Erythematosus, Systemic, Male, Middle Aged, Off-Label Use, Remission Induction, Rituximab, Severity of Illness Index, Treatment Outcome

الوصف: To evaluate the efficacy and safety of rituximab (RTX) in patients with systemic lupus erythematosus (SLE) refractory to standard therapy in the clinical practice setting.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/26053285; info:eu-repo/semantics/altIdentifier/wos/WOS:000360422100001; volume:33; issue:4; firstpage:449; lastpage:456; numberofpages:8; journal:CLINICAL AND EXPERIMENTAL RHEUMATOLOGY; http://hdl.handle.net/11577/3194819Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84939521363

الإتاحة: http://hdl.handle.net/11577/3194819Test

المؤلفون: Atzeni, Fabiola, Sarzi-Puttini, Piercarlo, Sebastiani, Marco, Panetta, Valentina, Salaffi, Fausto, Iannone, Florenzo, Carletto, Antonio, Foti, Rosario, Gremese, Elisa, Govoni, Marcello, Marchesoni, Antonio, Favalli, Ennio, Gorla, Roberto, Ramonda, Roberta, Ferraccioli, Gianfranco, Lapadula, Giovanni

المساهمون: Atzeni, Fabiola, Sarzi-Puttini, Piercarlo, Sebastiani, Marco, Panetta, Valentina, Salaffi, Fausto, Iannone, Florenzo, Carletto, Antonio, Foti, Rosario, Gremese, Elisa, Govoni, Marcello, Marchesoni, Antonio, Favalli, Ennio, Gorla, Roberto, Ramonda, Roberta, Ferraccioli, Gianfranco, Lapadula, Giovanni

مصطلحات موضوعية: Adalimumab, Adult, Antirheumatic Agent, Etanercept, Female, Human, Infection, Infliximab, Italy, Male, Middle Aged, Registrie, Spondylarthropathie, Surveys and Questionnaire, Tumor Necrosis Factor-alpha

الوصف: To determine the incidence of serious infections (SIs) among the spondyloarthropathy (SpA) patients from the "Gruppo Italiano per lo Studio delle Early Arthritis" (GISEA) registry and treated with tumour necrosis factor (TNF) inhibitors (TNFIs), and to identify the factors associated with the development of the infections.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/30767865; info:eu-repo/semantics/altIdentifier/wos/WOS:000473242000017; volume:37; issue:4; firstpage:649; lastpage:655; numberofpages:7; journal:CLINICAL AND EXPERIMENTAL RHEUMATOLOGY; http://hdl.handle.net/11577/3308919Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85069269152

الإتاحة: http://hdl.handle.net/11577/3308919Test

المؤلفون: Galli, Massimo, Antinori, Spinello, Atzeni, Fabiola, Meroni, Luca, Riva, Agostino, Scirè, Carlo, Adorni, Fulvio, Quartuccio, Luca, Sebastiani, Marco, Airò, Paolo, Bazzichi, Laura, Cristini, Francesco, Del Bono, Valerio, Manfredi, Andreina, Viapiana, Ombretta, De Rosa, Francesco, Favalli, Ennio, Petrelli, Enzo, Salvarani, Carlo, Govoni, Marcello, Corcione, Silvia, Scrivo, Rossana, Sarmati, Loredana, Lazzarin, Adriano, Grassi, Walter, Mastroianni, Claudio, Gaeta, Giovanni Battista, Ferraccioli, Gianfranco, Cutolo, Maurizio, De Vita, Salvatore, Lapadula, Giovanni, Matucci-Cerinic, Marco, Armignacco, Orlando, Sarzi-Puttini, Piercarlo

المساهمون: Galli, Massimo, Antinori, Spinello, Atzeni, Fabiola, Meroni, Luca, Riva, Agostino, Scirè, Carlo, Adorni, Fulvio, Quartuccio, Luca, Sebastiani, Marco, Airò, Paolo, Bazzichi, Laura, Cristini, Francesco, Del Bono, Valerio, Manfredi, Andreina, Viapiana, Ombretta, De Rosa, Francesco, Favalli, Ennio, Petrelli, Enzo, Salvarani, Carlo, Govoni, Marcello, Corcione, Silvia, Scrivo, Rossana, Sarmati, Loredana, Lazzarin, Adriano, Grassi, Walter, Mastroianni, Claudio, Gaeta, Giovanni Battista, Ferraccioli, Gianfranco, Cutolo, Maurizio, De Vita, Salvatore, Lapadula, Giovanni, Matucci-Cerinic, Marco, Armignacco, Orlando, Sarzi-Puttini, Piercarlo

مصطلحات موضوعية: Antirheumatic Agent, Arthritis, Rheumatoid, Coccidioidomycosi, Cryptococcosi, Histoplasmosi, Human, Lung Diseases, Fungal, Pneumonia, Pneumocysti, Pulmonary Aspergillosis

الوصف: Often life-threatening pulmonary fungal infections (PFIs) can occur in patients with rheumatoid arthritis (RA) receiving disease-modifying anti-rheumatic drugs (DMARDs). Most of the data concerning PFIs in RA patients come from case reports and retrospective case series. Of the ve most widely described PFIs, Pneumocystis jirovecii pneumonia (PJP) has rarely been seen outside Japan, pulmonary cryptococcosis has been diagnosed in only a small number of patients worldwide, pulmonary coccidioidomycosis has almost only been observed in endemic areas, the limited number of cases of pulmonary histoplasmosis have mainly occurred in the USA, and the rare cases of invasive pulmonary aspergillosis have only been encountered in leukopenic patients. Many aspects of the prophylaxis, diagnosis and treatment of PFIs in RA patients remain to be defined, as does the role of each DMARD in increasing the risk of infection, and the possibility of resuming biological and non-biological DMARD treatment after the infection has been cured. The recommendations for the management of PFIs described in this paper are the product of a consensus procedure promoted by the Italian group for the Study and Management of Infections in Patients with Rheumatic Diseases (the ISMIR group).

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/29185961; info:eu-repo/semantics/altIdentifier/wos/WOS:000418418300019; volume:35; issue:6; firstpage:1018; lastpage:1028; numberofpages:11; journal:CLINICAL AND EXPERIMENTAL RHEUMATOLOGY; http://hdl.handle.net/11562/989020Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85040565526

الإتاحة: http://hdl.handle.net/11562/989020Test

المؤلفون: Codullo, Veronica, Iannone, Florenzo, Sinigaglia, Luigi, Favalli, Ennio Giulio, Sarzi-Puttini, Piercarlo, Atzeni, Fabiola, Ferraccioli, Gianfranco, Gremese, Elisa, Carletto, Antonio, Giollo, Alessandro, Govoni, Marcello, Bergossi, Francesca, Galeazzi, Mauro, CANTARINI, LUCA, Salaffi, Fausto, Di Carlo, Marco, Bazzani, Chiara, Pellerito, Raffaele, Sebastiani, Marco, Ramonda, Roberta, Lapadula, Giovanni, Caporali, Roberto

المساهمون: Codullo, Veronica, Iannone, Florenzo, Sinigaglia, Luigi, Favalli, Ennio Giulio, Sarzi-Puttini, Piercarlo, Atzeni, Fabiola, Ferraccioli, Gianfranco, Gremese, Elisa, Carletto, Antonio, Giollo, Alessandro, Govoni, Marcello, Bergossi, Francesca, Galeazzi, Mauro, Cantarini, Luca, Salaffi, Fausto, Di Carlo, Marco, Bazzani, Chiara, Pellerito, Raffaele, Sebastiani, Marco, Ramonda, Roberta, Lapadula, Giovanni, Caporali, Roberto

مصطلحات موضوعية: Adalimumab, Adrenal Cortex Hormone, Adult, Aged, Antirheumatic Agent, Arthritis, Rheumatoid, Drug Therapy, Combination, Female, Human, Italy, Male, Methotrexate, Middle Aged, Remission Induction, Severity of Illness Index, Treatment Failure, Registries

الوصف: Targeted drugs against key pathogenetic molecules such as TNF-alpha have significantly improved outcomes in rheumatoid arthritis (RA). They are widely used in clinical practice and drug registries give us information to support their use. Adalimumab (ADA) is able to induce a comprehensive disease control in RA by achieving clinical, functional and radiographic control.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/28516879; info:eu-repo/semantics/altIdentifier/wos/WOS:000406877800015; volume:35; issue:4; firstpage:660-665; journal:CLINICAL AND EXPERIMENTAL RHEUMATOLOGY; http://hdl.handle.net/11577/3277129Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85028659468

الإتاحة: http://hdl.handle.net/11577/3277129Test

المؤلفون: Parisi, Federico, Paglionico, Annamaria, Varriano, Valentina, Ferraccioli, Gianfranco, Gremese, Elisa

المساهمون: Parisi, Federico, Paglionico, Annamaria, Varriano, Valentina, Ferraccioli, Gianfranco, Gremese, Elisa

مصطلحات موضوعية: adult-onset Still disease, anakinra, macrophage activation syndrome, myiocarditi, Adult, Antirheumatic Agent, Drug Resistance, Female, Human, Interleukin 1 Receptor Antagonist Protein, Myocarditi, Still's Disease, Adult-Onset, Medicine (all), Settore MED/16 - REUMATOLOGIA

الوصف: Rationale: Myocarditis is a rare but potentially fatal complication of Still's disease (about 7% of total cases). Patient concerns: A 42-year-old woman was admitted to our ward with high-grade fever, rash and polyarthralgia, lasting since 4 weeks and rapidly complicated by MAS and acute heart failure. Diagnoses: Adult Onset Still's Disease rapidly developping macrophage activation syndrome and disseminated intravascular coagulopathy, further complicated by iperacute myocarditis with cardiac arrest. Interventions: After failure of conventional therapies (steroids plus cyclosporine and then biological therapy with Anakinra 100 mg/day), the patient was treated with anakinra 100 mg sc 1 fl 4 times a day. Outcomes: Fast clinical and laboratoristic improvement and subsequent disease remission with complete recovery of cardiac function. Lessons: This is the first case report in which high doses of Anakinra have been used to treat a refractory AOSD complicated by MAS and myocarditis. In AOSD complicated by life-threatening conditions, probably we need to consider aggressive therapeutic approaches with higher doses of Il-1 receptor blocker to switch off the hyper-inflammation.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/28614216; info:eu-repo/semantics/altIdentifier/wos/WOS:000403594100002; volume:96; issue:24; firstpage:e6656; lastpage:N/A; issueyear:2017; journal:MEDICINE; http://hdl.handle.net/10807/122673Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85021973810; http://journals.lww.com/md-journalTest

الإتاحة: https://doi.org/10.1097/MD.0000000000006656Test
http://hdl.handle.net/10807/122673Test
http://journals.lww.com/md-journalTest

المؤلفون: Salaffi, Fausto, Di Carlo, Marco, Iannone, Florenzo, Fedele, Anna Laura, Epis, Oscar Massimiliano, Pellerito, Raffaele, Foti, Rosario, Passiu, Giuseppe, Punzi, Leonardo, Furini, Federica, Sarzi-Puttini, Piercarlo, Carletto, Antonio, Gremese, Elisa, Lapadula, Giovanni, Ferraccioli, Gianfranco

المساهمون: F. Salaffi, M. Di Carlo, F. Iannone, A.L. Fedele, O.M. Epi, R. Pellerito, R. Foti, G. Passiu, L. Punzi, F. Furini, P. Sarzi-Puttini, A. Carletto, E. Gremese, G. Lapadula, G. Ferraccioli

مصطلحات موضوعية: Biological therapie, Outcome measure, Rheumatoid arthriti, Ultrasonography, Abatacept, Aged, Antirheumatic Agent, Arthritis, Rheumatoid, Female, Hand Joint, Human, Longitudinal Studie, Male, Middle Aged, Severity of Illness Index, Treatment Outcome, Rheumatology, Anesthesiology and Pain Medicine, Settore MED/16 - Reumatologia

الوصف: Objective: To assess validity, responsiveness and interpretability of the UltraSound-CLinical ARthritis Activity (US-CLARA) index in patients with rheumatoid arthritis (RA). Methods: In this longitudinal study were involved RA patients starting treatment with abatacept. Subjects were followed along three visits in the first 6 months of therapy and underwent a comprehensive clinimetric evaluation. Validity was explored correlating the baseline scores and the cumulative inflammatory burden of the US-CLARA with the other composite indices applied. Sensitivity to change was assessed after 6 months of treatment in terms of internal and external responsiveness. Interpretability was defined in terms of determination of cutoffs against external criteria for remission (REM), low disease activity (LDA), moderate disease activity (MDA), and high disease activity (HDA) of SDAI. Results: One-hundred and thirty patients completed the study. Validity: moderate correlations were observed between US-CLARA and both DAS28-CRP and DAS28-ESR. Higher correlations were also found between US-CLARA and both SDAI and CDAI scores. Responsiveness: internal responsiveness was wide, with SRM and ES ranging from 0.91 to 1.51. US-CLARA responsiveness was similar to that of DAS28, SDAI, or CDAI. Similarly, the area under ROC curve (AUC-ROC) of US-CLARA gives identical results. The AUC of cumulative inflammatory burden, calculated during the 6-months follow-up of all combinations were highly correlated (p < 0.0001). Interpretability: cutoff values for REM, US-CLARA <2.0; for LDA, 2.0 ≤US-CLARA <3; for MDA, 3 ≤US-CLARA ≤4.8; for HDA, US-CLARA >4.8. Conclusion: The US-CLARA is valid and sensitive tool to assess disease activity in RA.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/29102157; info:eu-repo/semantics/altIdentifier/wos/WOS:000429082600003; volume:47; issue:5; firstpage:619; lastpage:629; numberofpages:11; journal:SEMINARS IN ARTHRITIS AND RHEUMATISM; http://hdl.handle.net/2434/640464Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85033478874

الإتاحة: https://doi.org/10.1016/j.semarthrit.2017.09.013Test
http://hdl.handle.net/2434/640464Test

المؤلفون: Iannone, Florenzo, Sinigaglia, Lugi, Favalli, Ennio Giulio, Sarzi Puttini, Piercarlo, Atzeni, Fabiola, Caporali, Roberto, Codullo, Veronica, Ferraccioli, Gianfranco, Gremese, Elisa, Carletto, Antonio, Giollo, Alessandro, Govoni, Marcello, Bergossi, Francesca, Galeazzi, Mauro, Cantarini, Luca, Salaffi, Fausto, Di Carlo, Marco, Bazzani, Chiara, Pellerito, Raffaele, SEBASTIANI, Marco, Ramonda, Roberta, Lapadula, Giovanni

المساهمون: Iannone, Florenzo, Sinigaglia, Lugi, Favalli, Ennio Giulio, Sarzi Puttini, Piercarlo, Atzeni, Fabiola, Caporali, Roberto, Codullo, Veronica, Ferraccioli, Gianfranco, Gremese, Elisa, Carletto, Antonio, Giollo, Alessandro, Govoni, Marcello, Bergossi, Francesca, Galeazzi, Mauro, Cantarini, Luca, Salaffi, Fausto, Di Carlo, Marco, Bazzani, Chiara, Pellerito, Raffaele, Sebastiani, Marco, Ramonda, Roberta, Lapadula, Giovanni

مصطلحات موضوعية: Drug survival, GISEA, HAQ, LORHEN, Activities of Daily Living, Adalimumab, Adult, Aged, Antirheumatic Agent, Arthriti, Rheumatoid, Biological Product, Disease Progression, Female, Human, Male, Middle Aged, Registrie, Remission Induction, Treatment Outcome, Rheumatology

الوصف: The purpose of the study was to estimate the clinical profile of naïve biological patients with rheumatoid arthritis (RA) starting adalimumab through 3-year calendar periods and their clinical outcomes such as drug survival and global clinical disease control (GCDC). RA patients starting adalimumab as first biological drug between 2003 and 2012 were subdivided in 3-year calendar periods. Survival on therapy was estimated using the Kaplan-Meier analysis. One and 2-year clinical response was assessed by calculating percentage of patients attaining GCDC (28-joint Disease Activity Score (DAS28) ≤ 2.6 + Health Assessment Questionnaire (HAQ) ≤ 0.5), low disease activity (DAS28 ≤ 3.2), remission (DAS28 ≤ 2.6) and good European League Against Rheumatism (EULAR) response. Multivariate regression models were used to assess baseline predictors of drug discontinuation or achievement of clinical remission. We recruited 1695 RA patients. Overall drug persistence at 3 years was 40.6 %, while the global rate of nonswitching patients was 54.7 %. Compared to 2003–2005, initiators in more recent years had a significantly lower 3-year crude drug retention rate (log rank, p < 0.0001) and a significantly higher rate of switching to alternative biologics (log rank, p < 0.0001). No difference in adverse events or effectiveness rate among the calendar periods was found. A substantial proportion of patients (up to 27 %) achieved GCDC at 2 years, regardless of the calendar period. In real-life setting, RA patients starting adalimumab in more recent years had a higher rate of drug discontinuation not related to ineffectiveness or side effects but to switching, probably due to a wider availability of biologics. A meaningful proportion of patients attained GCDC without any difference across calendar periods.

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000386362000003; volume:35; issue:11; firstpage:2649; lastpage:2656; numberofpages:8; journal:CLINICAL RHEUMATOLOGY; https://hdl.handle.net/11381/2977650Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84978828157; link.springer.de/link/service/journals/10067/index.htm

الإتاحة: https://doi.org/10.1007/s10067-016-3349-zTest
https://hdl.handle.net/11381/2977650Test

المؤلفون: Gremese, Elisa, Ferraccioli, Gianfranco

المساهمون: Iannone, Florenzo, Gremese, Elisa, Ferraccioli, Gianfranco, Lapadula, Giovanni

مصطلحات موضوعية: Adalimumab, Antirheumatic Agent, Arthritis, Rheumatoid, Chemical and Drug Induced Liver Injury, Etanercept, Female, Hepatitis C, Chronic, Human, Male, Rheumatology, Settore MED/16 - REUMATOLOGIA

الوصف: Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study. [Clin Rheumatol. 2015]

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/26113173; info:eu-repo/semantics/altIdentifier/wos/WOS:000372429000043; volume:35; issue:3; firstpage:839; lastpage:840; numberofpages:2; issueyear:2016; journal:CLINICAL RHEUMATOLOGY; http://hdl.handle.net/10807/94108Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84960437525; link.springer.de/link/service/journals/10067/index.htm

الإتاحة: https://doi.org/10.1007/s10067-015-2997-8Test
http://hdl.handle.net/10807/94108Test

المؤلفون: SEBASTIANI, Marco, Anelli, Maria Grazia, Atzeni, Fabiola, Bazzani, Chiara, Farina, Ilaria, Fedele, Anna Laura, Favalli, Ennio Giulio, Fineschi, Irene, Cino, Nicolò, Dal Forno, Ilaria, Gasparini, Stefania, Cassarà, Emanuele, Giardina, Rita, Bruschi, Eleonora, Addimanda, Olga, Cassone, Giulia, Lopriore, Simona, Sarzi Puttini, Piercarlo, Filippini, Matteo, Pignatti, Federica, Gremese, Elisa, Biggioggero, Martina, Manganelli, Stefania, Amato, Giorgio, Caimmi, Cristian, Salaffi, Fausto, Iannone, Florenzo, FERRI, Clodoveo, SANDRI, Gilda, Lapadula, Giovanni, Gorla, Roberto, Govoni, Marcello, Ferraccioli, Gianfranco, Marchesoni, Antonio, Galeazzi, Mauro, Foti, Rosario, Carletto, Antonio, Cantini, Fabrizio, Triolo, Giovanni, Epis, Oscar Massimiliano, SALVARANI, CARLO

المساهمون: Sebastiani, Marco, Anelli, Maria Grazia, Atzeni, Fabiola, Bazzani, Chiara, Farina, Ilaria, Fedele, Anna Laura, Favalli, Ennio Giulio, Fineschi, Irene, Cino, Nicolò, Dal Forno, Ilaria, Gasparini, Stefania, Cassarà, Emanuele, Giardina, Rita, Bruschi, Eleonora, Addimanda, Olga, Cassone, Giulia, Lopriore, Simona, Sarzi Puttini, Piercarlo, Filippini, Matteo, Pignatti, Federica, Gremese, Elisa, Biggioggero, Martina, Manganelli, Stefania, Amato, Giorgio, Caimmi, Cristian, Salaffi, Fausto, Iannone, Florenzo, Ferri, Clodoveo, Sandri, Gilda, Lapadula, Giovanni, Gorla, Roberto, Govoni, Marcello, Ferraccioli, Gianfranco, Marchesoni, Antonio, Galeazzi, Mauro, Foti, Rosario, Carletto, Antonio, Cantini, Fabrizio, Triolo, Giovanni, Epis, Oscar Massimiliano, Salvarani, Carlo

مصطلحات موضوعية: Anti-CD20, Methotrexate, Rheumatoid arthriti, Rituximab, Adult, Aged, Antibodie, Monoclonal, Murine-Derived, Antirheumatic Agent, Arthriti, Rheumatoid, Drug Therapy, Combination, Female, Human, Male, Middle Aged, Treatment Outcome, Registries

الوصف: Introduction Rituximab (RTX) is a monoclonal anti-CD20 antibody approved for the treatment of rheumatoid arthritis (RA) in association with methotrexate (MTX). Objectives To evaluate the efficacy and safety of RTX–MTX combination therapy compared with RTX alone in the treatment of RA. Methods We analyzed data from a prospective cohort study, the Italian biologic register GISEA, to investigate the efficacy and safety of rituximab. Moreover, the adverse events (AE) and the causes of discontinuation therapy were analyzed. Results We identified 338 RA patients, 162 treated with RTX and 176 with RTX–MTX. After 52 and 104 weeks of therapy the disease activity score in 28 joints and the Health Assessment Questionnaire Score were available in 168 patients (78 with RTX–MTX and 60 with RTX alone), showing significant reduction without differences among the two groups. AE were reported in 142 patients (42%), for a total of 368 recorded side effects. The majority (90.5%) of AE were mild to moderate in severity. Comparable percentages of severe AE were reported in the 2 groups (9.9% for RTX alone and 9.3% for RTX + MTX). A poor disease control was observed in 14.2% and 13.5% of patients treated with RTX + MTX and RTX, respectively; while 12 patients (4.5% in RTX + MTX, and 2.5% in RTX group) suspended therapy for AE. Conclusions RTX showed a good efficacy and safety profile in the real-life management of RA patients regardless of the association with MTX.

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000346418700008; volume:81; firstpage:508; lastpage:512; numberofpages:5; journal:JOINT BONE SPINE; https://hdl.handle.net/11381/2977556Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84922656307

الإتاحة: https://doi.org/10.1016/j.jbspin.2014.06.011Test
https://hdl.handle.net/11381/2977556Test

المؤلفون: Iannone, Florenzo, Gremese, Elisa, Gallo, Gaia, Sarzi-Puttini, Piercarlo, Botsios, Costantino, Trotta, Francesco, Gasperini, Stefania, Galeazzi, Mauro, Adami, Silvano, Cantini, Fabrizio, Sebastiani, Marco, Gorla, Roberto, Marchesoni, Antonio, Giardina, Annarita, Foti, Rosario, Mele, Angiola, Bruschi, Eleonora, Bagnato, Gianluca, Erre, Gian Luca, Lapadula, Giovanni, Scioscia, Crescenzio, Fedele, Anna Laura, Ferraccioli, Gianfranco, Atzeni, Fabiola, Bongiovanni, Sara, Punzi, Leonardo, Bernardi, Livio, Bagnari, Valentina, Govoni, Marcello, Grassi, Walter, Salaffi, Fausto, Manganelli, Stefania, Frati, Elena, Carletto, Antonio, Caimmi, Cristian, Palloni, Alice, Niccoli, Laura, Ferri, Clodoveo, Favalli, Ennio Giulio, Triolo, Giovanni, Di Gangi, Marcella

المساهمون: Iannone, Florenzo, Gremese, Elisa, Gallo, Gaia, Sarzi-Puttini, Piercarlo, Botsios, Costantino, Trotta, Francesco, Gasperini, Stefania, Galeazzi, Mauro, Adami, Silvano, Cantini, Fabrizio, Sebastiani, Marco, Gorla, Roberto, Marchesoni, Antonio, Giardina, Annarita, Foti, Rosario, Mele, Angiola, Bruschi, Eleonora, Bagnato, Gianluca, Erre, Gian Luca, Lapadula, Giovanni, Scioscia, Crescenzio, Fedele, Anna Laura, Ferraccioli, Gianfranco, Atzeni, Fabiola, Bongiovanni, Sara, Punzi, Leonardo, Bernardi, Livio, Bagnari, Valentina, Govoni, Marcello, Grassi, Walter, Salaffi, Fausto, Manganelli, Stefania, Frati, Elena, Carletto, Antonio, Caimmi, Cristian, Palloni, Alice, Niccoli, Laura, Ferri, Clodoveo, Favalli, Ennio Giulio, Triolo, Giovanni, Di Gangi, Marcella

مصطلحات موضوعية: DAS28, Disease remission, GISEA, HAQ, TNF-α inhibitor, Adolescent, Adult, Aged, 80 and over, Antirheumatic Agent, Arthritis, Rheumatoid, Biological Product, Drug Therapy, Combination, Etanercept, Female, Glucocorticoid, Human, Immunoglobulin G, Italy, Male, Methotrexate, Middle Aged, Prospective Studie, Receptors, Tumor Necrosis Factor, Registrie, Severity of Illness Index, Surveys and Questionnaire

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/23954923; info:eu-repo/semantics/altIdentifier/wos/WOS:000329941600005; volume:33; issue:1; firstpage:31; lastpage:37; numberofpages:7; journal:CLINICAL RHEUMATOLOGY; http://hdl.handle.net/11566/254519Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84897631607; link.springer.de/link/service/journals/10067/index.htm

الإتاحة: https://doi.org/10.1007/s10067-013-2348-6Test
http://hdl.handle.net/11566/254519Test